Drugs that contain Trifarotene

1. List of Aklief drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7807708 GALDERMA LABS LP Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof
Oct, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8470871 GALDERMA LABS LP Ligands that modulate RAR receptors
Dec, 2025

(2 years from now)

US8227507 GALDERMA LABS LP Ligands that modulate RAR receptors
Dec, 2025

(2 years from now)

US9084778 GALDERMA LABS LP Topical compositions containing a retinoid of the oil-in-water emulsion type
May, 2033

(10 years from now)

US9498465 GALDERMA LABS LP Topical compositions in the form of a gel containing a particular solubilized retinoid
May, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 4, 2024

NCE-1 date: October, 2023

Market Authorisation Date: 04 October, 2019

Treatment: Method of activating rargamma receptor; Topical treatment of acne vulgaris; Treatment of acne vulgaris

Dosage: CREAM;TOPICAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in